Arcadia Investment Management Corp MI Has $1.39 Million Stake in Zoetis Inc. (NYSE:ZTS)

Arcadia Investment Management Corp MI decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 1.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,552 shares of the company’s stock after selling 138 shares during the period. Arcadia Investment Management Corp MI’s holdings in Zoetis were worth $1,393,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Investors Asset Management of Georgia Inc. GA ADV lifted its position in Zoetis by 5.0% during the 4th quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 2,120 shares of the company’s stock worth $345,000 after acquiring an additional 101 shares during the last quarter. Suncoast Equity Management acquired a new position in shares of Zoetis during the fourth quarter valued at about $1,917,000. FDx Advisors Inc. raised its position in shares of Zoetis by 16.7% during the fourth quarter. FDx Advisors Inc. now owns 1,682 shares of the company’s stock valued at $274,000 after buying an additional 241 shares during the last quarter. Nicholson Wealth Management Group LLC raised its position in shares of Zoetis by 137.5% during the fourth quarter. Nicholson Wealth Management Group LLC now owns 7,875 shares of the company’s stock valued at $1,283,000 after buying an additional 4,559 shares during the last quarter. Finally, Tandem Investment Advisors Inc. acquired a new position in shares of Zoetis during the fourth quarter valued at about $32,185,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS opened at $157.38 on Friday. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The firm has a market capitalization of $70.47 billion, a PE ratio of 28.77, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90. The firm has a 50-day moving average price of $166.86 and a 200 day moving average price of $178.14.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.27%. Zoetis’s dividend payout ratio is 36.56%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ZTS. Stifel Nicolaus cut their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. Leerink Partners began coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective for the company. Morgan Stanley cut their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Finally, Barclays upped their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $214.90.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.